Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(17%)
Results Posted
33%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph early_phase_1
1
17%
Ph phase_1
4
67%
Ph phase_2
1
17%

Phase Distribution

5

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
unknown1
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (16.7%)
Phase 14 (66.7%)
Phase 21 (16.7%)

Trials by Status

completed350%
unknown117%
terminated117%
recruiting117%

Recent Activity

1 active trials
Showing 5 of 6
recruitingphase_2

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

NCT03970447
completedearly_phase_1

Study of Tinostamustine for Adjuvant Treatment of Glioblastoma

NCT05432375
completedphase_1

Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma

NCT03452930
completedphase_1

Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

NCT02576496
terminatedphase_1

Tinostamustine Conditioning and Autologous Stem Cell

NCT03687125
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03970447Phase 2

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Recruiting
NCT05432375Early Phase 1

Study of Tinostamustine for Adjuvant Treatment of Glioblastoma

Completed
NCT03452930Phase 1

Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma

Completed
NCT02576496Phase 1

Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Completed
NCT03687125Phase 1

Tinostamustine Conditioning and Autologous Stem Cell

Terminated
NCT03903458Phase 1

Tinostamustine and Nivolumab in Advanced Melanoma

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6